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ABSTRACT 
Background: The Losartan Intervention For End- 
point reduction (LIFE) study was a randomized, ouble- 
blind trial that compared the effects of losartan-based 
treatment with those of atenolol-based treatment on 
cardiovascular disease (CVD)-related morbidity and 
mortality in 9193 patients with hypertension and left- 
ventricular hypertrophy (LVH). Compared with ateno- 
lol, losartan reduced the combined risk for CVD-related 
morbidity and mortality by 13% (P = 0.021), and re- 
duced the risk for stroke by 25% (P = 0.001), with com- 
parable blood pressure control in both trial arms. 
Objective: The aim of this study was to analyze the 
cost-effectiveness of losartan compared with atenolol 
in the treatment of stroke from the Dutch health care 
perspective. 
Methods: Utilization of losartan and atenolol with- 
in the trial period (mean, 4.8 years) and an estimation 
of direct medical costs of stroke for The Netherlands 
were combined with estimates of reduction in life ex- 
pectancy through stroke. Medication costs and stroke 
incidence during 5.5 years of patient follow-up were 
estimated separately, adjusted for the baseline degree 
of LVH and Framingham risk score. To estimate life- 
time stroke costs, the cumulative incidence of stroke 
was multiplied by the lifetime direct medical costs at- 
tributable to stroke. All costs are in 2006 Dutch prices 
and discounted following the former (4% costs and 
effects) and new Dutch guideline (4% costs, 1.5% ef- 
fects) for conducting pharmacoeconomic analyses. 
Results: With 4% discounting, prevention of stroke 
was associated with a gain of 3.7 life-years. As a conse- 
quence, losartan treatment was associated with 0.059 life- 
year gained (LYG) per patient reated with losartan. Lo- 
sartan reduced stroke-related costs by C1076 (US $1349) 
per patient. After inclusion of study medication cost, 
net cost per patient was C51 ($64) higher for losartan 
than atenolol. The net cost per LYG was C864 ($1083), 
which is below the Dutch pharmacoeconomic thresh- 
old of C20,000/LYG (-$25,000/LYG) for accepting in- 
terventions. The corresponding probability of a cost- 
effectiveness ratio below this Dutch threshold was 0.95. 
Discounting money and health following the new 
Dutch guideline resulted in an even more favorable 
cost-effectiveness for losartan. 
Conclusions: Results from the present analysis sug- 
gest that, in The Netherlands, treatment with losartan 
compared with atenolol may well be a cost-effective in-
tervention based on the reduced risk for stroke observed 
in the LIFE trial. (Clin Ther. 2007;29:963-971) Copy- 
right © 2007 Excerpta Medica, Inc. 
Key words: angiotensin-II receptor blocker, losar- 
tan, stroke, cost-effectiveness. 
INTRODUCTION 
Cardiovascular disease (CVD) is a major cause of mor- 
tality and morbidity in The Netherlands as well as in 
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many other countries. 1 Due to aging of the population, 
CVDs present a heavy and growing burden to socie- 
ty. 2,3 In The Netherlands, costs of CVDs amount o up 
to 10% of the total health care budget, of which -28% 
is related to stroke. 4Stroke accounts for -3% per year 
of the total health care costs in some countries, includ- 
ing The Netherlands. 2,5,6 Based on demographic 
changes and treatment improvements associated with 
improved life expectancies for surviving patients with 
stroke, an increase in the prevalence of future strokes 
can be expected. 7-9 Direct costs for stroke consist main- 
ly of costs for institutional care (eg, hospitalization, 
nursing home, rehabilitation center), of which costs for 
hospitalizations are dominant in the first year after 
stroke and nursing home costs are dominant in the re- 
maining lifetime. 2,5,1°q6 Despite improvements, only a 
few effective treatments are available for managing 
stroke. Hypertension is an important risk factor that 
contributes to the risk for CVDs, including stroke. 17,18 
Thus, primary prevention in patients with hyperten- 
sion using blood pressure-lowering a ents may offer a 
relevant opportunity to reduce the medical and eco- 
nomic burden caused by stroke. 17,19 
The Losartan Intervention For Endpoint reduction 
(LIFE) study 20,21 was designed to assess the long-term 
effects of the angiotensin-II receptor blocker (ARB) 
losartan compared with those of the ~3-blocker ateno- 
lol in hypertensive patients with left-ventricular hyper- 
trophy (LVH) on the combined end point of CVD- 
related morbidity and mortality. Losartan resulted in 
a statistically significant effect on the combined end 
point, notably associated with a 25% reduction in the 
incidence of stroke (relative risk [RR] = 0.75; P = 
0.001).21 The LIFE study found that losartan may pre- 
vent stroke and stroke-associated morbidity, despite 
comparable blood pressure control for both atenolol 
and losartan. Based on a literature review, Dfez 22 sug- 
gested that losartan (and other ARBs) possibly has 
properties, independent of the antihypertensive ef- 
fects, that are associated with a lower prevalence of 
strokes as found during the LIFE study. In this eco- 
nomic analysis, the findings of the LIFE study were 
adapted to the Dutch situation to estimate the cost- 
effectiveness ofpreventing stroke by means of treatment 
with losartan compared with treatment with atenolol. 
In The Netherlands, losartan has been approved for 
treatment of essential hypertension, type 2 diabetes 
with comorbid proteinuria (to delay progression of 
kidney failure), and hypertension i  patients with LVH 
(to reduce the risk for cardiovascular morbidity and 
mortality). Our study analyzed the pharmacoeconom- 
ic profile of losartan. Next to evidence with respect to 
the effectiveness oftreatment, costs and cost-effectiveness 
become more and more important not only for reim- 
bursement costs of the medications used but also re- 
ductions in other direct costs (ie, hospitalizations, 
rehabilitation, etc.) contribute to possible lower total 
costs or even cost savings within a health care system. 
For the treatment of essential hypertension, antihyper- 
tensive agents other than ARBs (eg, losartan) are rec- 
ommended in treatment guidelines for general prac- 
titioners, 23 as these generally less expensive agents have 
been associated with sufficient blood pressure control. 
In patient groups with more severe disease, significant- 
ly favorable results--in terms of lower risk for cardio- 
vascular and renal disease--were found for ARBs 
compared with other antihypertensive agents. Previous 
comparable analyses of losartan and other ARBs have 
found economic favorability (cost savings) in patients 
with type 2 diabetes with nephropathy. 24,25 To calcu- 
late the cost-effectiveness of losartan treatment in pa- 
tients with LVH, results from the LIFE study were 
applied to The Netherlands. 
MATERIALS AND METHODS 
Design of the LIFE Study 
The study design and results of the LIFE study have 
been reported elsewhere. 2°,21 It was a randomized, 
double-blind trial that compared the effects of the ARB 
losartan with those of the 13-blocker atenolol on CVD- 
related morbidity (stroke and myocardial infarction) 
and mortality. The LIFE population consisted of 9193 hy- 
pertensive patients included from >800 clinical cen- 
ters in different countries (Scandinavian countries, the 
United Kingdom, and the United States) were included. 
Eligible participants were aged 55 to 80 years, had es- 
sential hypertension (systolic/diastolic blood pressure 
160-200/95-115 mm Hg) and LVH (ascertained by 
electrocardiography) and were assigned to once-daily 
treatment with losartan or atenolol, administered for a 
mean (SD) duration of 250 (47) weeks. For at least 
4 years, doses of losartan and atenolol (mean [SD] doses, 
82 [24] and 79 [26] rag, respectively) were increased in 
an attempt o lower blood pressure to a target of 
<140/<90 mm Hg. Patients were regularly monitored 
and followed up for at least 4 years, and until then 
1040 patients had reported a primary end point 
(stroke, myocardial infarction, and/or cardiovascular 
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death). Baseline demographic, linical characteristics, 
and medical history of participating patients are pre- 
sented in Table I, which shows that the losartan and 
atenolol groups closely matched with respect o the 
baseline characteristics. 
The LIFE study found a statistically significant re- 
duction with losartan in the combined end point of in- 
cidence of stroke, myocardial infarction, and cardio- 
vascular death of 13% compared with atenolol with 
comparable blood pressure control (RR = 0.87; 95% 
CI, 0.77-0.98; P = 0.021). For the single end points of 
myocardial infarction (RR = 1.07; 95% CI, 0.88- 
1.31; P = NS) and CVD-related death (RR = 0.89; 
95% CI, 0.73-1.07; P = NS), no statistically signifi- 
cant differences were found between losartan and 
atenolol. However, for the single end point of stroke, 
losartan was associated with a significantly (25%) 
lower incidence (RR = 0.75; 95% CI, 0.63-0.89; P = 
0.001) compared with the atenolol-treated group. 21 In 
addition, the incidence of new-onset diabetes was 
25% lower with losartan than with atenolol (RR = 
0.75; 95% CI, 0.63-0.88; P = 0.001), the adverse- 
event profile was more favorable, and the number of 
patients remaining on treatment was higher (84% vs 
80% of follow-up) in the losartan-treated group. 21 
The present economic study focused on the findings 
for stroke only. 
Economic  Assessment  
The present study was an incremental cost-effective- 
ness comparison of losartan and atenolol in costs per 
life-year gained (LYG) from the Dutch health care 
perspective. The between-treatment difference in to- 
tal costs form the numerator of the incremental cost- 
effectiveness ratio, with total costs defined as those of 
the study medication and direct lifetime medical costs 
attributable to strokes observed uring the 5.5-year trial 
period of the LIFE study. The denominator was the 
number of LYGs for losartan versus atenolol. Costs 
and health were discounted against 4%. 
In sensitivity analysis, we applied different discount 
rates based on the recent change in the discounting 
procedure in the Dutch guidelines for pharmacoeco- 
nomic research. In particular, it was just decided that 
updated guidelines would advocate differential dis- 
count rates for money and health, at 4% and 1.5%, 
respectively. 26-31 To investigate the effects of applying 
discount rates according to both options, both pro- 
cedures were applied. Additionally, we conducted a
Table I. Baseline demographic and clinical characteris- 
tics of the Losartan Intervention For Endpoint 
reduction (LIFE) study population. 21 
Losartan Atenolol 
Characteristic (n = 4605) (n = 4588) 
Age, mean (SD), y 66.9 (7.0) 66.9 (7.0) 
Sex, no. (%) 
Female 2487 (54) 2476 (54) 
Male 2118(46) 2112(46) 
Blood pressure, 
mean (SD), mm Hg 
Systolic 174.3 (14.2) 174.5 (14.4) 
Diastolic 97.9 (8.8) 97.7 (9.0) 
Framingham risk score, 0.223 0.225 
mean (SD) (0.095) (0.096) 
Medical history, no. (%) 
Cardiovascular disease ~ 1203 (26) 1104 (24) 
Coronary heart disease ~ 771 (17) 698 (15) 
Isolated systolic 
hypertensionf 660 (14) 666 (15) 
Cerebrovascular disease 369 (8) 359 (8) 
Peripheral vascular 
disease 276 (6) 244 (5) 
Atrial fibrillation 150 (3) 174 (4) 
Diabetes mellitus 586 (13) 609 (13) 
Data from Dahl6fet al. 
*P < 0.05. 
tDefined as _>160/90 mm Hg. 
sensitivity analysis on the major cost driver in our 
analysis--stroke. 
Cumulat ive Incidence o f  Stroke 
In the LIFE trial, a 25% RR reduction in first stroke 
was found with losartan. To use the reduced stroke in- 
cidence in our economic assessment, the absolute risk 
for stroke after a 5.5-year within-trial period was cal- 
culated. This absolute risk reduction reflects the differ- 
ence in cumulative incidence of stroke between the 
losartan- and atenolol-treated groups. The cumulative 
incidence of stroke after the 5.5-year within-trial peri- 
od was estimated using the cumulative incidence com- 
peting risk method to account for the possibility of 
non-stroke-related death without prior stroke. 32 Based 
on the clinical assessment i  the LIFE study, we adjust- 
ed for baseline severity of LVH and Framingham risk 
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score. 21 To account for censoring due to incomplete 
patient follow-up, up to the 5.5 years within trial peri- 
od, the mean duration of study medication administra- 
tion (in days) was estimated using a 2-stage method, to 
determine the relationship between cumulative num- 
ber of days on each dose of study medication and sur- 
vival. 33 In particular, in patients with a duration of 
follow-up <5.5 years, medication use was extrapolated 
up to the full period based on the mean use during ac- 
tual follow-up. 
Unit Costs of Medical Resource Use 
To estimate costs from the Dutch health care per- 
spective, all randomized patients in the trial were in- 
cluded based on the intent-to-treat principle. Total 
direct costs were defined as the sum of costs of study 
medication during the 5.5-year within-trial period and 
estimated lifetime costs attributable to strokes. 
Costs for study medication were estimated by mul- 
tiplying study medication utilization during the LIFE 
study by unit costs in The Netherlands. In patients 
who experienced stroke, study medication costs after 
the stroke were excluded. Study medication utilization 
was based on the exact durations and doses of the 
study medications, as recorded during the patient- 
specific follow-up within LIFE. Unit costs for study 
medication were based on 2006 Dutch prices 34 for 
losartan 50 and 100 mg at C0.63 (US $0.79) and C1.07 
($1.34), respectively, and for atenolol 50 and 100 mg 
at C0.08 ($0.10) and C0.12 ($0.15), respectively. In 
addition, 6% value-added tax and the pharmacists' 
prescription fee (C6.10; $7.65) were included. 
The costs for stroke used in this analysis were 
based on a specific estimate of the stroke-related costs 
in The Netherlands, 1°verified by means of other esti- 
mates for stroke costs. 2,5,6,11-14,16,35 Total stroke costs 
were estimated by multiplying the lifetime costs due to 
managing stroke with the cumulative incidence of 
stroke over 5.5 years in the LIFE trial. 
Life Expectancy 
Gender- and age-specific life expectancy without 
stroke was estimated using Dutch life tables matched 
to the LIFE patient population. 36 Life expectancy with 
stroke was estimated with a Weibull model 37 applied 
to data from LIFE, with baseline severity of LVH, 
Framingham risk score, sex, and age as covariates. 
LYGs for losartan versus atenolol due to stroke risk 
reduction were estimated by multiplying the absolute 
risk reduction in stroke during the 5.5-year LIFE 
study by the number of additional life-years expected 
by preventing a stroke. 
Cost-Effectiveness Analysis 
For cost-effectiveness analysis, all costs and effects 
were respectively discounted according to both dis- 
counting options (4% costs and effects vs 4% costs 
and 1.5% effects). The 95% CIs and acceptance prob- 
abilities were based on a log-normal stroke cost distri- 
bution and the nonparametric bootstrap (1000 rep- 
licates). 33,38 Acceptance probabilities were calculated 
using the informal Dutch willingness-to-pay (WTP) 
threshold of C20,000/LYG (~$25,000/LYG) for ac- 
cepting pharmacotherapeutic interventions. All costs 
are reported in 2006 Euros. 
RES U LTS 
Overview 
First-year and lifetime costs of stroke were estimat- 
ed at C16,775 ($21,025) and C46,445 ($58,213) per 
patient, respectively. Compared with that of atenolol, 
the costs per patient of losartan was Cl128 ($1414) 
higher during the LIFE-trial follow-up. However, lo- 
sartan was associated with a significantly lower 
stroke-related cost per patient by C1076 ($1349). The 
reduction in stroke-related per-patient cost offset 95% 
of the increase in medication cost and was due to a 
lower incidence of stroke for losartan at 5.5 years 
(4.9%) compared with atenolol (6.5%) (P = 0.003). 
Table II shows the results of per-patient direct costs 
and incidence of stroke. 
In patients who did not experience stroke, we esti- 
mated a discounted mean life expectancy of 11.6 years, 
whereas patients with stroke had an estimated is- 
counted life expectancy of 7.9 years. Thus, prevention 
of stroke was associated with 3.7 discounted (4%) 
LYGs per stroke patient, implying 0.059 LYGs per pa- 
tient with losartan treatment (0.016 x 3.7). Table III 
shows the results. 
After inclusion of stroke-related costs and study 
medication costs, the net cost per patient was C51 
($64) higher with losartan compared with that of 
atenolol. The net cost per LYG was C864 ($1083), 
which is below the Dutch threshold of C20,000/LYG 
(~$25,000). 41
Figure 1 shows the plane of bootstrap replicates for 
incremental direct costs and LYGs. Fifty-four percent of 
the replicates were in the upper right hand, indicating 
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Table II. Per-patient direct costs (C [US $]) and incidence of stroke (no. [%] of patients) during follow-up of the 
kosartan Intervention For Endpoint reduction (LIFE) study population. 21Data are mean (SD) unless oth- 
erwise noted. 
Parameter Losartan Atenolol Difference 
Costs 
Study medication 1265 (1586) 138 (173) 
Stroke 3317 (4157) 4393 (5506) 
Net 4582 (5743) 4531 (5679) 
Cumulative incidence of stroke (at 5.5 years) 0.049 0.065 
1128 (1414) 
-1076 ~ (-1349) 
51 (64) (95% CI, -601 to 703) 
0.016 (95% CI, 0.006 to 0.026) 
~Negative costs indicate cost savings. 
Table III. Life expectancy (LE), life-years gained (LYG), and incremental cost per LYG. 
Parameter Former PE Guideline s9 New PE Guideline 4° 
Discounted LE without stroke, mean, y 
Discounted LE with stroke, mean, y 
Expected LYG by preventing a stroke, mean, y 
LYG for Iosartan due to stroke risk reduction, 
mean (95% CI), y 
Incremental cost per LYG for Iosartan, 





0.059 (0.020 to 0.097) 
864 (-7308 to 27,607) 




0.081 (0.029 to 0.134) 
630 @5245 to 20,158) 
790 @6575 to 25,272) 
PE = pharmacoeconomic. 
an intervention with increased cost and improved effec- 
tiveness. However, the remaining replicates were in the 
lower right-hand quadrant, indicating cost savings. 
Figure 2 presents the probability of cost-effectiveness 
for a range of pharmacoeconomic thresholds. From 
the Dutch health care perspective, the probability of a 
cost-effectiveness ratio below the Dutch threshold of 
C20,000/LYG (-$25,000/LYG) was estimated at 0.95. 
In the sensitivity analysis, outcomes of the incre- 
mental cost-effectiveness of losartan versus atenolol for 
the change in discount rate for health gains in The 
Netherlands was compared. Discounting LYG at 1.5% 
resulted in a mean discounted life expectancy with- 
out stroke of 14 years, whereas patients who experi- 
enced stroke would have an average discounted life 
expectancy of 8.9 years. The 5.1-years' difference re- 
flects the expected LYGs resulting from preventing a 
stroke. LYGs with losartan--as the product of the ab- 
solute risk reduction for stroke (1.6%) and expected 
LYGs by preventing stroke (5.1 years)--is estimated 
at 0.081 (P = 0.002). The estimated incremental cost 
per LYG with losartan was C630 ($790) (Table III). 
Figure 2 shows results for discounting health gains at 
1.5%. The suggested probability of a cost-effectiveness 
ratio below the Dutch threshold of C20,000/LYG 
($25,000/LYG) was estimated at 0.97. Sensitivity analy- 
sis on the major cost driver--stroke costs (+25% and 
-25%)--indicated a range of cost savings to C5441 
($6822). 
DISCUSSION 
The LIFE study found a significantly ower prevalence 
of stroke in losartan-treated patients compared with 
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[1 C = US $1.25372]). Dashed line indicates 1.5% discounting of effects; solid line indicates 4% dis- 
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sure control. 21 In this economic assessment of the LIFE 
study adapted to The Netherlands, stroke costs were 
C1076 ($1349) lower in the losartan-treated group, 
corresponding with C51 ($64) net incremental direct 
costs. With an extended estimated life expectancy due 
to the reduction in stroke associated with losartan 
treatment, estimated incremental cost-effectiveness 
was C864/LYG ($1083/LYG). For losartan, the esti- 
mated likelihood of falling below the Dutch threshold 
of C20,000/LYG ($25,000/LYG) was 95%. 
Comparable economic assessments based on the 
LIFE study have been conducted in Switzerland, 
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Sweden, the United Kingdom, and Canada. These stud- 
ies also found favorable stimated economic outcomes 
with losartan, with potential per-patient cost-savings of 
C19 ($25) in Switzerland 42 and cost-effectiveness of 
C4188 ($5249), C3195 ($4005), and Can $1337 (US 
$1003) per quality-adjusted life year (QALY) gained in 
Sweden, 43 the United Kingdom, 44 and Canada, 4s re- 
spectively. Despite differences in pharmacoeconomic 
guidelines (eg, regarding perspective, discount rates, 
type of analysis, model used), costs included and pur- 
pose of the study (eg, registration, justification of pre- 
scribing practice of health care professionals, reimburse- 
ment decisions, clinical guidelines), country-specific 
results were in the same direction varying from net cost 
savings for losartan in Switzerland to low net costs per 
LYG or QALY gained in the other countries. 
Several imitations of the present study should be 
acknowledged. Because the data were derived from a 
clinical trial, the period to which the data referred was 
limited and lacked long-term follow-up, so model- 
based extrapolations were necessary, with uncertainty 
obviously surrounding such extrapolations for LYGs 
and QALYs. Also, treatment compliance may not fully 
reflect what happens in clinical practice. Furthermore, 
no survival data were available that exactly matched 
the cohort in the clinical trial. Finally, perspective of 
the present study was limited to that of the health care 
sector only, rather than analyzing the full scope with- 
in a societal perspective. 
In addition to the efficacy of losartan found in the 
LIFE study, the results of the present cost-effectiveness 
analysis for this drug may be partly explained by a 
lower rate of adverse vents and greater tolerability of 
losartan, which may have resulted in better treatment 
compliance with losartan compared with atenolol. 
Results from an observational study by Conlin et a146 
support his suggestion with regard to ARBs, such as 
losartan, by claiming a substantially greater persis- 
tence for ARBs compared with other classes of antihy- 
pertensives, including atenolol. 
In The Netherlands, ~3-blockers and diuretics are 
recommended as first-line treatment of hypertension 
in the general practitioners' guidelines. This, together 
with relatively high use (-30% of all prescriptions in 
The Netherlands in 200547)--compared with other 
classes of antihypertensive agents (ie, diuretics and 
calcium channel blockers)--suggests that atenolol is a 
proper comparator for losartan. 4s-s° However, the re- 
suits of clinical trials in general provide evidence for 
selected patient groups, which may not allow for di- 
rect extrapolation to the general patient population in 
clinical practice, sl
In the present analysis, we included only stroke- 
related costs and excluded costs related to comorbidities 
and related use of drugs other than study drugs. The 
inclusion of stroke-related costs only could, however, 
be a concern in the relatively high-risk patients in the 
LIFE study. However, there were almost no statistical 
differences in prevalence of comorbidities between the 
losartan- and atenolol-treated groups. Differences 
found were related to compliance/persistence and new- 
onset diabetes, with losartan being associated with 
higher and lower rates, respectively. The prevalence of 
new-onset diabetes was 25% lower in the losartan- 
treated group compared with the atenolol-treated 
group (P = 0.001). 21 This finding suggests that the re- 
suits of the present study may show a further cost ad- 
vantage of losartan if we also included (direct) costs 
associated with additional cardiovascular events and 
(co-)morbidities, uch as new-onset diabetes and ad- 
verse events. 
In the sensitivity analysis, discounting health gains 
lower at 1.5% versus 4% as in the baseline analysis 
was associated with a favorable pharmacoeconomic 
outcome for losartan, with the probability of being 
below the Dutch threshold at 97%. The new pharma- 
coeconomic guideline favors pharmacoeconomic out- 
comes of (primary) prevention programs, compared 
with the old one, in which costs and effects were both 
discounted at 4%. In literature there is discussion 
about the choice of applying the same or different dis- 
count rates for costs and effects, 2 Varying the major 
cost driver also resulted in a favorable pharmacoeco- 
nomic outcome following the Dutch WTP threshold. 
The present study included LIFE study data from 
various countries, due to the multinational approach 
of the LIFE study. A limitation of the present econom- 
ic assessment was the assumption that findings from 
the LIFE study would be similar in Dutch patients, 
whereas no Dutch patients were included in the LIFE 
trial. In short, imperfections can be found in the trans- 
ferability of data from a clinical trial such as LIFE to 
The Netherlands due to, for example, epidemiologic 
and demographic factors. However, the present study 
can at least be seen as providing an indication for posi- 
tive health effects at a low additional cost per LYG. 
The results from the present analysis uggest that drug 
prices alone do not provide the full economic picture; 
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in particular, downstream savings may cause that the 
initially more expensive option is in the end still a 
cost-effective option. Trials tailored to the Dutch situa- 
tion are needed to confirm the present findings for 
The Netherlands. 
CONCLUSIONS 
In the present cost analysis, treatment with losartan 
could be considered a cost-effective intervention com- 
pared with atenolol based on the reduced risk for 
stroke observed in the LIFE study for The Nether- 
lands. This notion should be considered in the devel- 
opment of clinical guidelines, in addition to clinical 
efficacy, tolerability, and experience with treatment 
options in general clinical practice. 
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